Use of zoledronic acid in the treatment of Paget’s disease

References

• AdamsonBBGallacherSJByarsJMineralisation defects with pamidronate therapy for Paget’s diseaseLancet19933421459607902484
   PubMed Web of Science ®Google Scholar
• AmanatNMcDonaldMGodfreyCOptimal timing of a single dose of zoledronic acid to increase strength in rat fracture repairJ Bone Miner Res2007228677617371160
   PubMed Web of Science ®Google Scholar
• Arden-CordoneMSirisESLylesKWAntiresorptive effect of a single infusion of microgram quantities of zoledronate in Paget’s disease of boneCalcif Tissue Int19976041589115157
   PubMed Web of Science ®Google Scholar
• BezziMHasmimMBielerGZoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/AktJ Biol Chem2003278436031412933798
   PubMed Web of Science ®Google Scholar
• BlackDMDelmasPDEastellROnce-yearly zoledronic acid for treatment of postmenopausal osteoporosisN Engl J Med200735618092217476007
   PubMed Web of Science ®Google Scholar
• BodyJJClinical research update: zoledronateCancer19978016997019362440
   PubMed Web of Science ®Google Scholar
• BrownJPHoskingDJSte-MarieLRisedronate, a highly effective, short-term oral treatment for Paget’s disease: a dose-response studyCalcif Tissue Int1999649399914313
   PubMed Web of Science ®Google Scholar
• BucklerHFraserWHoskingDSingle infusion of zoledronate in Paget’s disease of bone: a placebo- controlled, dose-ranging studyBone19992481S85S10321935
   PubMed Web of Science ®Google Scholar
• ChangJTGreenLBeitzJRenal failure with the use of zoledronic acidN Engl J Med200334916769 discussion 1676–914573746
   PubMed Web of Science ®Google Scholar
• ChungGKeenRWZoledronate treatment in active Paget’s diseaseAnn Rheum Dis200362275612594123
   PubMed Web of Science ®Google Scholar
• CooperCSchafheutleKDennisonEThe epidemiology of Paget‘s disease in Britain: is the prevalence decreasing?J Bone Miner Res19991419279933472
   PubMed Web of Science ®Google Scholar
• CundyTWattieDBuschSPaget‘s disease in New Zealand: is it changing?Bone1999247S9S10321917
   PubMed Web of Science ®Google Scholar
• DaubineFLe GallCGasserJAntitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasisJ Natl Cancer Inst2007993223017312309
   PubMed Web of Science ®Google Scholar
• DemulderATakahashiSSingerFRAbnormalities in osteoclast precursors and marrow accessory cells in Paget’s diseaseEndocrinology19931331978827691583
   PubMed Web of Science ®Google Scholar
• DerenneSAmiotMBarilleSZoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environmentJ Bone Miner Res19991420485610620064
   PubMed Web of Science ®Google Scholar
• DolgitserMSternLKatzLMManag Care Interface200720334017405580
   PubMedGoogle Scholar
• DuranASerranoMLeitgesMThe atypical PKC-interacting protein p62 is an important mediator of RANK-activated osteoclastogenesisDev Cell20046303914960283
   PubMed Web of Science ®Google Scholar
• EvansRADunstanCRHillsEPathologic fracture due to severe osteomalacia following low-dose diphosphonate treatment of Paget’s disease of boneAust N Z J Med19831327796416243
   PubMedGoogle Scholar
• FleischHDevelopment of bisphosphonatesBreast Cancer Res2002430411879557
   PubMed Web of Science ®Google Scholar
• FournierPBoissierSFilleurSBisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated ratsCancer Res20026265384412438248
   PubMed Web of Science ®Google Scholar
• GralowJTripathyDManaging metastatic bone pain: the role of bisphosphonatesJ Pain Symptom Manage2007334627217397707
   PubMed Web of Science ®Google Scholar
• GreenJRMullerKJaeggiKAPreclinical pharmacology of CGP 42’446, a new, potent, heterocyclic bisphosphonate compoundJ Bone Miner Res19949745518053405
   PubMed Web of Science ®Google Scholar
• GreenJRSeltenmeyerYJaeggiKARenal tolerability profile of novel, potent bisphosphonates in two short-term rat modelsPharmacol Toxicol199780225309181601
   PubMedGoogle Scholar
• HockingLJLucasGJDaroszewskaADomain-specific mutations in sequestosome 1 (SQSTM1) cause familial and sporadic Paget’s diseaseHum Mol Genet2002112735912374763
   PubMed Web of Science ®Google Scholar
• HoskingDLylesKBrownJPLong-term control of bone turnover in Paget’s disease with zoledronic acid and risedronateJ Bone Miner Res200722142817032148
   PubMed Web of Science ®Google Scholar
• HughesDEWrightKRUyHLBisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivoJ Bone Miner Res1995101478878686503
   PubMed Web of Science ®Google Scholar
• KhanSABrennanPNewmanJPaget’s disease of bone and unvaccinated dogsBone19961947508830987
   PubMed Web of Science ®Google Scholar
• KraneSMEtidronate disodium in the treatment of Paget’s disease of boneAnn Intern Med198296619256280538
   PubMed Web of Science ®Google Scholar
• KukitaAChenuCMcManusLMAtypical multinucleated cells form in long-term marrow cultures from patients with Paget’s diseaseJ Clin Invest199085128062318982
   PubMed Web of Science ®Google Scholar
• LiptonAThe safety of zoledronic acidExpert Opin Drug Saf200763051317480179
   PubMed Web of Science ®Google Scholar
• MacarolVFraunfelderFTPamidronate disodium and possible ocular adverse drug reactionsAm J Ophthalmol199411822048053468
   PubMed Web of Science ®Google Scholar
• MaerevoetMMartinCDuckLOsteonecrosis of the jaw and bisphosphonatesN Engl J Med200535399102 discussion 99–10216003838
   PubMed Web of Science ®Google Scholar
• MarkowitzGSFinePLStackJIToxic acute tubular necrosis following treatment with zoledronate (Zometa)Kidney Int200364281912787420
   PubMed Web of Science ®Google Scholar
• MartenALilienfeld-ToalMBuchlerMWZoledronic acid has direct antiproliferative and antimetastatic effect on pancreatic carcinoma cells and acts as an antigen for delta2 gamma/delta T cellsJ Immunother200730370717457212
   PubMed Web of Science ®Google Scholar
• MarxREPamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemicJ Oral Maxillofac Surg2003611115712966493
   PubMed Web of Science ®Google Scholar
• MarxRESawatariYFortinMBisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatmentJ Oral Maxillofac Surg20056315677516243172
   PubMed Web of Science ®Google Scholar
• McClungMReckerRMillerPIntravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronateBone200741122817468062
   PubMed Web of Science ®Google Scholar
• MeeAPParamyxoviruses and Paget’s disease: the affirmative viewBone19992419S21S10321921
   PubMed Web of Science ®Google Scholar
• MerigoEManfrediMMeletiMJaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): a four-case reportJ Oral Pathol Med200534613716202082
   PubMed Web of Science ®Google Scholar
• MillerPDBrownJPSirisESA randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget’s disease of bone. Paget’s Risedronate/Etidronate Study GroupAm J Med19991065132010335722
   PubMed Web of Science ®Google Scholar
• MillsBGSingerFRWeinerLPCell cultures from bone affected by Paget’s diseaseArthritis Rheum1980231115206158956
   PubMed Web of Science ®Google Scholar
• Morales-PigaAABachiller-CorralFJAbrairaVIs clinical expressiveness of Paget’s disease of bone decreasing?Bone20023039940311856648
   PubMed Web of Science ®Google Scholar
• OdvinaCVZerwekhJERaoDSSeverely suppressed bone turnover: a potential complication of alendronate therapyJ Clin Endocrinol Metab200590129430115598694
   PubMed Web of Science ®Google Scholar
• OttSMTen years of alendronate treatment for osteoporosis in postmenopausal womenN Engl J Med20043511902 author reply 190–215250064
   PubMed Web of Science ®Google Scholar
• RalstonSHAfzalMAHelfrichMHMulticenter blinded analysis of RT-PCR detection methods for paramyxoviruses in relation to Paget’s disease of boneJ Bone Miner Res2007225697717227218
   PubMed Web of Science ®Google Scholar
• RebelABasleMPouplardATowards a viral etiology for Paget’s disease of boneMetab Bone Dis Relat Res1981323586762481
   PubMedGoogle Scholar
• ReidIRBrownJPBurckhardtPIntravenous zoledronic acid in postmenopausal women with low bone mineral densityN Engl J Med20023466536111870242
   PubMed Web of Science ®Google Scholar
• ReidIRMillerPLylesKComparison of a single infusion of zoledronic acid with risedronate for Paget’s diseaseN Engl J Med200535389890816135834
   PubMed Web of Science ®Google Scholar
• ReidIRSirisEAlendronate in the treatment of Paget’s disease of boneInt J Clin Pract Suppl199910162612669742
   PubMedGoogle Scholar
• RendinaDMossettiGVicecontiRRisedronate and pamidronate treatment in the clinical management of patients with severe Paget’s disease of bone and acquired resistance to bisphosphonatesCalcif Tissue Int2004751899615148558
   PubMed Web of Science ®Google Scholar
• RimaBKGassenUHelfrichMHThe pro and con of measles virus in Paget’s disease: conJ Bone Miner Res2002172 author reply 2293
   Web of Science ®Google Scholar
• RosenLSGordonDKaminskiMZoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic Lesions of multiple myeloma: a phase III, double-blind, comparative trialCancer J200173778711693896
   PubMed Web of Science ®Google Scholar
• RosenCJBrownSSevere hypocalcemia after intravenous bisphosphonate therapy in occult vitamin D deficiencyN Engl J Med20033481503412686715
   PubMed Web of Science ®Google Scholar
• SirisERoodmanGDFavusMJPrimer on the Metabolic Bone Diseases2003Washington, DCASBMR495506
   Google Scholar
• SirisEWeinsteinRSAltmanRComparative study of alendronate versus etidronate for the treatment of Paget’s disease of boneJ Clin Endocrinol Metab19968196178772558
   PubMed Web of Science ®Google Scholar
• TrombettiAArlotMThevenonJEffect of multiple intravenous pamidronate courses in Paget’s disease of boneRev Rhum Engl Ed1999664677610567975
   PubMedGoogle Scholar
• van StaaTPSelbyPLeufkensHGIncidence and natural history of Paget’s disease of bone in England and WalesJ Bone Miner Res2002174657111878305
   PubMed Web of Science ®Google Scholar
• WhyteMPWenkertDClementsKLBisphosphonate-induced osteopetrosisN Engl J Med20033494576312890844
   PubMed Web of Science ®Google Scholar
• WidlerLJaeggiKAGlattMHighly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa)J Med Chem20024537213812166945
   PubMed Web of Science ®Google Scholar